Catalyst
Monitor the trial's outcomes regarding feasibility and acceptability of the new CDS tool, as well as any subsequent changes in treatment adherence rates.
Humanexa recommends Monitor.
Date
June 30, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.